Publicaties

Postel MG, Huurne ED ter, de Haan HA, van der Palen J, DeJong CA.  2015.  A 9-month follow-up of a 3-month web-based alcohol treatment program using intensive asynchronous therapeutic support.. Am J Drug Alcohol Abuse. 41(4):309-16.

Otte RA, Verbrugge CAG, Dijkstra BAG.  2016.  Aanbevelingen voor ketenzorg bij GHB gerelateerde problemen. NISPA GHB Onderzoek.

Middeldorp J, Smit R, Post H, Koerts J, van Oene GH de Weert.  2015.  Aandacht voor somatiek bij verslaafden. Verslaving. 11

Dijkstra B.A.G., Malcontent J., van Dongen A..  2019.  Aanpak GHB-problematiek binnen en buiten de regio - de Etten-Leurse aanpak.

DeJong CA, Galyuk TM, de Backer G, Beers E, Loonen AJ.  2009.  Abuse of quetiapine: two addicted patients with borderline personality disorder. Nederlands Tijdschrift Geneeskunde. 153(14)

Joosten EAG, Wamel A, Joosten EAG, Dijkstra BAG.  2020.  Achtergronddocument Handreiking voor GHB behandeling.

Martin-Santos R, Crippa JA, Batalla A, Bhattacharyya S, Atakan Z, Borgwardt S, Allen P, Seal M, Langohr K, Farré M et al..  2012.  Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers.. Curr Pharm Des. 18(32):4966-79.

Carpentier PJ.  2012.  Addiction and the role of childhood externalising disorders. Sociale Wetenschappen. Ph. D.:182.

Carpentier PJ, Knapen LJM, Van Gogh MT, Buitelaar JK, DeJong CA.  2012.  Addiction in developmental perspective: influence of conduct disorder severity, subtype, and attention-deficit hyperactivity disorder on problem severity and comorbidity in adults with opioid dependence.. J Addict Dis. 31(1):45-59.

DeJong CA, Van de Wetering BJM.  2009.  Addiction medicine is an attractive field for young physicians-a call for a European initiative for the training in addiction medicine. Addiction. 7(104):9.

DeJong CA, Luycks L.  2015.  Addiction medicine training in the Netherlands. el-Guebaly N, Carrà G, Galanter M (Eds) Textbook of Addiction Treatment: International Perspectives. . XII

DeJong CA, Willems JC, Schippers GM, Hendriks VM.  1995.  The Addiction Severity Index: reliability and validity in a Dutch alcoholic population.. Int J Addict. 30(5):605-16.

Ayu AParawita, Iskandar S, Siste K, DeJong CA, Schellekens A.  2016.  Addiction training for health professionals as an antidote to the addiction health burden in Indonesia.. Addiction. 111(8):1498-9.

Markus W, Hornsveld HK, Burk WJ, van Oene GH de Weert, Becker ES, DeJong CAJ.  2020.  Addiction-Focused Eye Movement Desensitization and Reprocessing Therapy as an Adjunct to Regular Outpatient Treatment for Alcohol Use Disorder: Results From a Randomized Clinical Trial.. Alcohol Clin Exp Res. 44(1):272-283.

Schellekens A, de Bruijn ERA, van Lankveld CAA, Hulstijn W, Buitelaar JK, DeJong CA, Verkes RJ.  2010.  Alcohol dependence and anxiety increase error-related brain activity.. Addiction. 105(11):1928-34.

van Duijvenbode N, VanDerNagel JEL, Didden R.  2019.  Alcohol (mis)use in individuals with mild to borderline intellectual disability. Neuroscience of alcohol.

de Haan L, de Haan HA, Olivier B, Verster JC.  2012.  Alcohol mixed with energy drinks: methodology and design of the Utrecht Student Survey. Int J Gen Med. 5(2):10.

de Haan HA, DeJong CA.  2009.  Alexithymia en alcoholverslaving: consequenties voor de behandeling. Verslavingsgeneeskunde: Psychofarmacologie, psychiatrie en somatiek.

de Haan HA.  2014.  Alexithymia in patients with substance use disorders.

de Haan HA, van der Palen J, Wijdeveld AGM, Buitelaar JK, DeJong CA.  2014.  Alexithymia in patients with substance use disorders: State or trait? Psychiatry Res.

de Haan HA, Joosten EAG, Wijdeveld AGM, Boswinkel PB, van der Palen J, DeJong CA.  2012.  Alexithymia is not a stable personality trait in patients with substance use disorders.. Psychiatry Res. 198(1):123-9.

van Schouwenburg MR, Zwiers MR, van der Schaaf ME, Geurts DEM, Schellekens A, Buitelaar JK, Verkes RJ, Cools AR.  2013.  Anatomical connection strength predicts dopaminergic drug effects on fronto-striatal function. Psychopharmacology. 227(3):521-31.

Batalla A, Vera M, Torra M, Parellada E.  2010.  Antipsychotic treatment in a patient with schizophrenia undergoing hemodialysis.. J Clin Psychopharmacol. 30(1):92-4.

Batalla A, Bargalló N, Gassó P, Molina O, Pareto D, Mas S, Roca JM, Bernardo M, Lafuente A, Parellada E.  2015.  Apoptotic markers in cultured fibroblasts correlate with brain metabolites and regional brain volume in antipsychotic-naive first-episode schizophrenia and healthy controls.. Transl Psychiatry. 5:e626.

Koster RA, Alffenaar JWC, Greijdanus B, VanDerNagel JEl, Uges DRA.  2014.  Application of sweat patch screening for 16 drugs and metabolites using a fast and highly selective LC-MS/MS method.. Ther Drug Monit. 36(1):35-45.